Envision Healthcare Holdings, Inc. Form 8-K September 07, 2016

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 7, 2016

ENVISION HEALTHCARE HOLDINGS, INC.

(Exact name of each registrant as specified in its charter)

Delaware (State or other jurisdiction

001-36048 (Commission

45-0832318 (IRS Employer

	of incorporation)	File Numbers)	Identification Nos.)	
	6363 South Fiddlers Green Circle, 14th Greenwood Village, Colora (Address of principal executive offi	ndo	80111 (Zip Code)	
(303) 495-1200				
	(Each r	registrant s telephone number, includir	ng area code)	
			-	
	(Former r	name or former address, if changed sine	ce last report)	
	ck the appropriate box below if the Form 8-K for ollowing provisions (see General Instruction A		sfy the filing obligation of the registrant under any of	
x	Written communications pursuant to	Rule 425 under the Securities A	Act (17 CFR 230.425)	
0	Soliciting material pursuant to Rule	e 14a-12 under the Exchange Ac	et (17 CFR 240.14a-12)	
o 240	Pre-commencement communication .14d-2(b))	ns pursuant to Rule 14d-2(b) un	der the Exchange Act (17 CFR	
0	Pre-commencement communication	ns pursuant to Rule 13e-4(c) und	der the Exchange Act (17 CFR 240.13e-4(c))	

Item 8.01. Other Events.

On September 7, 2016, Envision Healthcare Holdings, Inc. (Envision) and AmSurg Corp. (AmSurg) received notice that the Antitrust Division of the State of Florida Attorney General s office has completed its inquiry into the proposed merger between AmSurg and Envision and is taking no action.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
Number Description

99.1 Press Release dated September 7, 2016.

No Offer or Solicitation / Additional Information and Where to Find It

This communication is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval with respect to the proposed business combination between Envision and AmSurg or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. The proposed business combination between Envision and AmSurg will be submitted to their respective shareholders for consideration. On August 4, 2016, AmSurg caused its newly formed, wholly owned subsidiary, New Amethyst Corp. (New Amethyst), to file with the Securities and Exchange Commission (the SEC) a Registration Statement on Form S-4 (File No. 333-212885) that constitutes a prospectus of New Amethyst and a preliminary joint proxy statement of Envision and AmSurg, and will also constitute a prospectus of New Amethyst. Envision and AmSurg will deliver the joint proxy statement/prospectus to their respective shareholders as required by applicable law. This communication is not a substitute for any prospectus, proxy statement or any other document that may be filed with the SEC in connection with the proposed business combination. Investors and shareholders are urged to read carefully and in their entirety the preliminary joint proxy statement/prospectus and any other relevant documents that are filed with the SEC when they become available because they contain important information about the proposed business combination and related matters. Investors and shareholders may obtain free copies of the preliminary joint proxy statement/prospectus and other documents containing important information about Envision, AmSurg and New Amethyst, once such documents are filed with the SEC, through the website maintained by the SEC at www.sec.gov. Envision and AmSurg make available free of charge at www.evhc.net and www.amsurg.com, respectively (in the Investors section), copies of materials they file with, or furnish to, the SEC.

Participants in The Merger Solicitation

Envision, AmSurg and certain of their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from the stockholders of Envision and shareholders of AmSurg in connection with the proposed business combination. Information about the directors and executive officers of Envision is set forth in its proxy statement for its 2016 annual meeting of stockholders filed with the SEC on March 23, 2016. Information about the directors and executive officers of AmSurg is set forth in its proxy statement for its 2016 annual meeting of shareholders filed with the SEC on April 22, 2016 and its Annual Report on Form 10-K for

the year ended December 31, 2015 filed with the SEC on February 25, 2016. These documents can be obtained free of charge from the sources indicated above. Other information regarding those persons who are, under the rules of the SEC, participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, are included in the preliminary joint proxy statement/prospectus, and more complete information will be available in the definitive joint proxy statement/final prospectus.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENVISION HEALTHCARE HOLDINGS, INC.

(Registrant)

September 7, 2016 By: /s/ Craig A. Wilson

Craig A. Wilson

Senior Vice President, General Counsel and Secretary

3